2DT Panoramica delle azioni Amneal Pharmaceuticals, Inc. insieme alle sue consociate, sviluppa, produce, commercializza e distribuisce in tutto il mondo farmaci generici, iniettabili, biosimilari e specialità farmaceutiche di marca. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Amneal Pharmaceuticals, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Amneal Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$7.10 Massimo di 52 settimane US$8.55 Minimo di 52 settimane US$4.76 Beta 1.1 Variazione di 1 mese -10.13% Variazione a 3 mesi -7.79% Variazione di 1 anno 35.24% Variazione a 3 anni 87.83% Variazione a 5 anni 59.91% Variazione dall'IPO -61.43%
Notizie e aggiornamenti recenti
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide Feb 19
Amneal Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 28, 2025 Jan 29
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin Jan 23
Insufficient new directors Dec 30
Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist Nov 22
Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023) Nov 10 Vedi altri aggiornamenti
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide Feb 19
Amneal Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 28, 2025 Jan 29
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin Jan 23
Insufficient new directors Dec 30
Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist Nov 22
Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023) Nov 10
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024 Nov 08
New major risk - Shareholder dilution Nov 08
Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 09
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials Aug 20
Insider recently sold €703k worth of stock Aug 18
Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023) Aug 11
Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024 Aug 09
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules Aug 08
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags Jul 30
Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 12
Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant Jul 10
Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar Jul 03
Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies Jun 06
Independent Director recently sold €236k worth of stock May 21
First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) May 04
Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose Apr 25
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA) Apr 19
Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024 Apr 11
Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024 Mar 23
Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022) Mar 04
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 Mar 01
Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024 Feb 01 Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension
Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022) Nov 09 Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023 Oct 24
Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 06 Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection
Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease Aug 25
Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022) Aug 06
Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023 Aug 05
Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics Jul 27
Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023 Jul 07
Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter Jul 04
Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable Jun 15
Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States May 17
First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022) May 10
Insufficient new directors May 10
First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022) May 07
Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023 May 06
Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021) Mar 04
Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023 Feb 01
Insufficient new directors Jan 20
Insufficient new directors Jan 01
Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval Dec 21
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States Nov 23
Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease Nov 12
Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021) Nov 05 Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022
Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection Nov 03
Amneal Pharmaceuticals, Inc. Announces Management Changes Nov 01
Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022 Oct 07
Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS Oct 04
Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty Sep 07
Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease Sep 01
Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose Aug 12
Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021) Aug 06
Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022 Aug 06
High number of new directors Aug 04
Amneal Pharmaceuticals, Inc. Appoints Deborah M. Autor to Board of Directors Aug 04
Amneal Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022 Jul 09
Amneal Pharmaceuticals, Inc. Announces Class Action Lawsuit Settlement Updates Jun 07
Amneal Pharmaceuticals, Inc. Launches LYVISPAH for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders Jun 03
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) May 28
First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.045 profit in 1Q 2021) May 05
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022 May 05
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly) Apr 14
Amneal Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 08 Amneal Pharmaceuticals, Inc. Reports Asset Impairment Charges for the Three Months Ended December 31, 2021
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 03
Amneal Pharmaceuticals, Inc. Receives Approval of Releukotm Mar 03
Amneal Pharmaceuticals, Inc. Expands Injectables Portfolio with 4 New Products Feb 18
Amneal Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022 Feb 05
Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2021 Jan 12
Co-Founder recently bought €553k worth of stock Dec 18
Co-Founder recently bought €553k worth of stock Dec 18
Amneal Pharmaceuticals, Inc. Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations Aug 26
Second quarter 2021 earnings released: EPS US$0.098 (vs US$0.081 loss in 2Q 2020) Aug 10
Amneal Pharmaceuticals, Inc. Receives Approval for Generic TobraDex Jul 20
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab Jun 18
Amneal Pharmaceuticals, Inc Announces That the Food and Drug Administration Recently Accepted Amneal’s 505(B)(2) New Drug Application for A Newly Licensed Dihydroergotamine Jun 08 Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended March 31, 2021
First quarter 2021 earnings released: EPS US$0.045 (vs US$0.78 in 1Q 2020) May 08
New 90-day high: €5.04 Mar 13
Investor sentiment improved over the past week Mar 11
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) acquired a sterile injectables manufacturing facility of Igenius Life Science LLP for approximately $8.1 million. Mar 10 Rendimenti per gli azionisti 2DT DE Pharmaceuticals DE Mercato 7D -4.1% -0.2% -1.3% 1Y 35.2% -16.2% 14.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 2DT ha superato il German Pharmaceuticals che ha restituito -16.2 % nell'ultimo anno.
Rendimento vs Mercato: 2DT ha superato il mercato German che ha restituito 14.9 % nell'ultimo anno.
Volatilità dei prezzi Is 2DT's price volatile compared to industry and market? 2DT volatility 2DT Average Weekly Movement 4.6% Pharmaceuticals Industry Average Movement 4.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.5%
Prezzo delle azioni stabile: 2DT non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di 2DT è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2002 7,850 Chirag Patel amneal.com
Amneal Pharmaceuticals, Inc. insieme alle sue consociate, sviluppa, produce, commercializza e distribuisce in tutto il mondo farmaci generici, iniettabili, biosimilari e specialità farmaceutiche di marca. L'azienda opera attraverso tre segmenti: Generici, Specialità e AvKARE. Il segmento Generics offre prodotti orali solidi, in polvere, liquidi, iniettabili sterili, spray nasali, inalatori e respiratori, biosimilari, oftalmici, film, cerotti transdermici e prodotti topici a rilascio immediato ed esteso.
Mostra di più Amneal Pharmaceuticals, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Amneal Pharmaceuticals con la sua capitalizzazione di mercato? 2DT statistiche fondamentali Capitalizzazione di mercato €2.32b Guadagni(TTM ) -€175.64m Ricavi(TTM ) €2.55b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 2DT Conto economico (TTM ) Ricavi US$2.68b Costo del fatturato US$1.70b Profitto lordo US$979.05m Altre spese US$1.16b Guadagni -US$184.45m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
Feb 28, 2025
Utile per azione (EPS) -0.60 Margine lordo 36.53% Margine di profitto netto -6.88% Rapporto debito/patrimonio netto -7,524.6%
Come si è comportato 2DT nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/20 17:11 Prezzo dell'azione a fine giornata 2025/02/20 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche Amneal Pharmaceuticals, Inc. è coperta da 20 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Balaji Prasad Barclays Balaji Prasad Barclays Gary Nachman BMO Capital Markets Equity Research
Mostra 17 altri analisti 
